1. Home
  2. JAZZ

JAZZ

Jazz Pharmaceuticals plc (Ireland)

Logo Jazz Pharmaceuticals plc (Ireland)

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Founded: 2003 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN
Market Cap: 6.8B IPO Year: 2007
Target Price: $193.43 AVG Volume (30 days): 622.8K
Analyst Decision: Buy Number of Analysts: 15
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 6.10 EPS Growth: N/A
52 Week Low/High: $110.42 - $146.70 Next Earning Date: 05-01-2024
Revenue: $3,834,204,000 Revenue Growth: 4.78%
Revenue Growth (this year): 9.2% Revenue Growth (next year): 7.09%

Share on Social Networks: